# Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients

> **NCT02825420** · — · COMPLETED · sponsor: **PharmaMar** · enrollment: 220 (actual)

## Conditions studied

- Relapsed Ovarian Cancer

## Interventions

- **DRUG:** trabectedin

## Key facts

- **NCT ID:** NCT02825420
- **Lead sponsor:** PharmaMar
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-28
- **Primary completion:** 2019-09-18
- **Final completion:** 2019-09-18
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2021-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02825420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02825420, "Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02825420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*